Published On: 8/28/2020

Target RWE Builds Growing COVID-19 Data Set of 70,000+ Patients, Announces Published Data Findings

Company rapidly accumulates COVID-19 patient data from 350+ hospitals across 41 states

DURHAM, N.C., August 28, 2020 /BUSINESS WIRE/ -- Target RWE, a leading real-world evidence (RWE) solutions company for the pharmaceutical and biotech industries, announced its quickly growing COVID-19 data set of more than 70,000 patients to support global research and healthcare partners as they respond to the coronavirus pandemic. The initial characteristics and outcomes from the data set have been published in the peer-reviewed journal Clinical Infectious Diseases (https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1268/5898276).

“The COVID-19 pandemic has amplified the need for information about the clinical course of this illness,” said Michael W. Fried, MD, FAASLD, chief medical officer of Target RWE and lead author on the publication. “Analyzing real-world data allows us to better understand the natural history of this disease, risk factors for poor outcomes, and acquire robust information on safety and effectiveness of drugs being used to treat COVID-19.”

Target RWE has quickly accumulated deidentified real-time data from hospitals across all geographic regions of the United States. With more than 70,000 patients, Target RWE’s COVID-19 data set will continue to grow to support and provide valuable information to healthcare partners.

In parallel, Target RWE has completed an initial analysis on its COVID-19 data set of characteristics and outcomes. The data published in Clinical Infectious Diseases captured more than 11,000 COVID-19 patients at 245 hospitals across 38 states in the country.

Key findings from Target RWE’s published data includes:

• The most common comorbidities among hospitalized patients included hypertension (46.7%), diabetes (27.8%), cardiovascular disease (18.6%), obesity (16.1%), and chronic kidney disease (12.2%).
• Mortality among hospitalized patients was 21.4% and increased to 70.5% among those on mechanical ventilation.
• Older age, male sex, preexisting chronic kidney disease, and cardiovascular disease were independently associated with worse outcomes.
• Over 4,000 patients had been treated with hydroxychloroquine and remdesivir was starting to be utilized to treat hospitalized patients.

“This data set continues to expand, and ongoing analyses will evaluate trends in outcomes over time. It includes special populations such as pediatric patients and novel therapeutic regimens that are being utilized in clinical practice, which will continue to inform best practices for the medical community,” said Robert S. Brown, Jr. MD, MPH, professor of medicine at Weill Cornell Medical Center and co-author on the study.

Other hospital data, including coding and billing, will be incorporated to provide a comprehensive view of the COVID-19 patient journey, including outcomes. These data can greatly facilitate COVID-19 treatment and prevention research currently underway by informing protocol design or acting as a control arm in situations where there are no other means to do so.

“As the incidence of COVID-19 infection continues to grow, there is an urgent need to capture important patient data so both researchers and healthcare providers better understand the disease progression and their most effective management options,” said Target RWE CEO Neal Bibeau. “We want to provide actionable real-world data that is needed to quickly inform diagnostic and treatment strategies, as well as rapidly evolving clinical trials for potential treatments and vaccines. Our data is meticulously curated and available for detailed analysis within days of treatment. I am pleased that our COVID-19 data set has grown significantly since the initial analysis was performed and now represents more than 70,000 hospitalized patients.”

Target RWE has developed its own COVID-19 observational clinical trial (https://clinicaltrials.gov/ct2/show/NCT04331886) to additionally follow patients diagnosed with the virus to generate valuable real-world data.